← Leaderboards
Daniel A. Haber
Massachusetts General Hospital
$29,412,047
Attributed
$40,818,476
Total exposure
15
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,259,268 · 16
By mechanism
R01$16,166,458 · 6
U01$10,900,164 · 2
P01$8,440,792 · 2
U54$4,581,672 · 1
R37$3,861,606 · 1
T32$3,738,815 · 1
Top collaborators
- Mehmet Toner19 shared
- Shyamala Maheswaran15 shared
- Lecia V. Sequist6 shared
- Alice T Shaw2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Mehmet Toner$56,861,630
- J. Keith Joung$24,183,955
- Miguel Nicolas Rivera$4,920,300
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorCellsNeoplastic CellGeneticResponseCancer CellCell LineResistanceMolecularMicrofluidicsNeoplasm Circulating CellsBiologicalPropertyNeoplasm MetastasisBloodIn VitroBaseTechnologySamplingMutationSuccessAffectPathway Interactions
Grant awards (87)
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$647,628
R01 · FY2025 · CA
Training Program in Cancer Biology and Therapeutics$633,473
T32 · FY2025 · CA · contact PI
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$453,440
R01 · FY2025 · CA
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$420,000
R01 · FY2025 · CA · contact PI
Training Program in Cancer Biology and Therapeutics$645,802
T32 · FY2024 · CA · contact PI
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$615,247
R01 · FY2024 · CA
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$430,769
R01 · FY2024 · CA
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$399,000
R01 · FY2024 · CA · contact PI
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$634,675
R01 · FY2023 · CA
Training Program in Cancer Biology and Therapeutics$523,031
T32 · FY2023 · CA · contact PI
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$443,269
R01 · FY2023 · CA
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$420,000
R01 · FY2023 · CA · contact PI
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$631,907
R01 · FY2022 · CA
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$594,889
U01 · FY2022 · CA
Training Program in Cancer Biology and Therapeutics$461,088
T32 · FY2022 · CA · contact PI
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$443,269
R01 · FY2022 · CA
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$366,678
R01 · FY2022 · CA · contact PI
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$644,804
R01 · FY2021 · CA
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$534,584
U01 · FY2021 · CA
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$452,315
R01 · FY2021 · CA
Training Program in Cancer Biology and Therapeutics$403,575
T32 · FY2021 · CA · contact PI
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$374,162
R01 · FY2021 · CA · contact PI
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$607,028
U01 · FY2020 · CA
Training Program in Cancer Biology and Therapeutics$386,395
T32 · FY2020 · CA · contact PI
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$374,162
R01 · FY2020 · CA · contact PI
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$588,815
U01 · FY2019 · CA
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$362,936
R01 · FY2019 · CA · contact PI
Training Program in Cancer Biology and Therapeutics$290,832
T32 · FY2019 · CA · contact PI
Point-of care Microfluidics for Early Detection of Cancer$2,082,080
U01 · FY2018 · EB
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$607,028
U01 · FY2018 · CA
Training Program in Cancer Biology and Therapeutics$394,619
T32 · FY2018 · CA · contact PI
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells$374,162
R01 · FY2018 · CA · contact PI
Point-of care Microfluidics for Early Detection of Cancer$2,082,080
U01 · FY2017 · EB
Modeling and Circumventing EMT to Suppress Metastasis$357,979
R01 · FY2017 · CA · contact PI
Point-of care Microfluidics for Early Detection of Cancer$2,082,080
U01 · FY2016 · EB
Modeling and Circumventing EMT to Suppress Metastasis$357,979
R01 · FY2016 · CA · contact PI
Point-of care Microfluidics for Early Detection of Cancer$1,721,580
U01 · FY2015 · EB
Modeling and Circumventing EMT to Suppress Metastasis$357,979
R01 · FY2015 · CA · contact PI
Modeling and Circumventing EMT to Suppress Metastasis$347,240
R01 · FY2014 · CA · contact PI
Modeling and Circumventing EMT to Suppress Metastasis$357,979
R01 · FY2013 · CA · contact PI
P1 - Clinical Correlations of WTX Inactivation in Wilms Tumor$249,390
P50 · FY2013 · CA · contact PI
Data Production, and Informatics and Integration$1,803,000
U54 · FY2012 · HG · contact PI
Circumventing Acquired Resistance to Growth Factor Receptor Kinase Inhibitors$356,257
R01 · FY2012 · CA · contact PI
P1 - Clinical Correlations of WTX Inactivation in Wilms Tumor$268,415
P50 · FY2012 · CA · contact PI
Data Production, and Informatics and Integration$1,913,709
U54 · FY2011 · HG · contact PI
Functional Properties of the Wilms' Tumor Gene WT1$423,106
R37 · FY2011 · CA · contact PI
Circumventing Acquired Resistance to Growth Factor Receptor Kinase Inhibitors$356,257
R01 · FY2011 · CA · contact PI
P1 - Clinical Correlations of WTX Inactivation in Wilms Tumor$255,328
P50 · FY2011 · CA · contact PI
Data Production, and Informatics and Integration$864,963
U54 · FY2010 · HG · contact PI
Functional Properties of the Wilms' Tumor Gene WT1$436,192
R37 · FY2010 · CA · contact PI
Circumventing Acquired Resistance to Growth Factor Receptor Kinase Inhibitors$367,275
R01 · FY2010 · CA · contact PI
P1 - Clinical Correlations of WTX Inactivation in Wilms Tumor$269,410
P50 · FY2010 · CA · contact PI
Functional Properties of the Wilms' Tumor Gene WT1$436,192
R37 · FY2009 · CA · contact PI
Circumventing Acquired Resistance to Growth Factor Receptor Kinase Inhibitors$366,238
R01 · FY2009 · CA · contact PI
Circumventing Acquired Resistance to Growth Factor Receptor Kinase Inhibitors$350,413
R01 · FY2009 · CA · contact PI
Clinical Correlations of WTX Inactivation in Wilms Tumor$270,218
P50 · FY2009 · CA · contact PI
Functional Properties of the Wilms' Tumor Gene WT1$436,192
R37 · FY2008 · CA · contact PI
Circumventing Acquired Resistance to Growth Factor Receptor Kinase Inhibitors$364,163
R01 · FY2008 · CA · contact PI
Functional Properties of the Wilm's Tumor Gene WT1$410,088
R37 · FY2007 · CA · contact PI
Genetic Models of Cellular Proliferation$1,745,196
P01 · FY2006 · CA · contact PI
Functional Properties of the Wilm's Tumor Gene WT1$422,336
R37 · FY2006 · CA · contact PI
Targets of Ewing Sarcoma-Wilms Tumor 1 Oncoprotein$242,606
R01 · FY2006 · CA · contact PI
Genetic Models of Cellular Proliferation$1,740,567
P01 · FY2005 · CA
Functional Properties of the Wilm's Tumor Gene WT1$432,500
R37 · FY2005 · CA
Targets of Ewing Sarcoma-Wilms Tumor 1 Oncoprotein$248,445
R01 · FY2005 · CA
Genetic Models of Cellular Proliferation$1,694,060
P01 · FY2004 · CA
Functional Properties of the Wilm's Tumor Gene WT1$432,500
R37 · FY2004 · CA
FUNCTIONAL CHARACTERIZATION OF BRCA1$326,667
R01 · FY2004 · CA
Targets of Ewing Sarcoma-Wilms Tumor 1 Oncoprotein$248,445
R01 · FY2004 · CA
Genetic Models of Cellular Proliferation$1,650,801
P01 · FY2003 · CA
Functional Properties of the Wilm's Tumor Gene WT1$432,500
R37 · FY2003 · CA
FUNCTIONAL CHARACTERIZATION OF BRCA1$317,149
R01 · FY2003 · CA
Targets of Ewing Sarcoma-Wilms Tumor 1 Oncoprotein$248,445
R01 · FY2003 · CA
Genetic Models of Cellular Proliferation$1,610,168
P01 · FY2002 · CA
FUNCTIONAL PROPERTIES OF THE WILMS TUMOR GENE WT1$329,272
R01 · FY2002 · CA
FUNCTIONAL CHARACTERIZATION OF BRCA1$307,914
R01 · FY2002 · CA
Targets of Ewing Sarcoma-Wilms Tumor 1 Oncoprotein$266,695
R01 · FY2002 · CA
G2 checkpoint genes in breast cancer susceptibiity$0
P50 · FY2002 · CA
Screen for genes targeted by homozygous deletion during cancer progression$0
P01 · FY2002 · CA
FUNCTIONAL PROPERTIES OF THE WILMS TUMOR GENE WT1$321,639
R01 · FY2001 · CA
FUNCTIONAL CHARACTERIZATION OF BRCA1$288,668
R01 · FY2001 · CA
MUTATIONAL ANALYSIS OF P53 RELATED GENES$127,500
R21 · FY2001 · CA
G2 checkpoint genes in breast cancer susceptibiity$0
P50 · FY2001 · CA
FUNCTIONAL PROPERTIES OF THE WILMS TUMOR GENE WT1$314,231
R01 · FY2000 · CA
FUNCTIONAL CHARACTERIZATION OF BRCA1$278,100
R01 · FY2000 · CA
MUTATIONAL ANALYSIS OF P53 RELATED GENES$129,500
R21 · FY2000 · CA
G2 checkpoint genes in breast cancer susceptibiity$0
P50 · FY2000 · CA